GlassScriptPhysician profile
Jonathan W Mooney
NPI 1427603935
$7,930.56
in general payments reported to CMS, 2019-2025
14 companies · $3,660 in 2025
The $3,660 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $586 · 2022: $655 · 2023: $1,343 · 2024: $1,687 · 2025: $3,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,455 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,455.08 |
| Education | $234.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,288.18 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $1,287.92 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,242.40 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $844.72 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $825.53 | 2021-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $685.46 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $606.53 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Vanda Pharmaceuticals INC. | $379.98 | 2021-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $354.17 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $263.94 | 2023-2025 | Auvelity, Sunosi |
| Indivior INC. | $74.40 | 2022-2023 | Perseris |
| Braeburn INC. | $31.25 | 2024 | Brixadi |
| Baxter Healthcare | $26.86 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.22 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.